Chairpersons: F. Alhenc-Gelas (Paris, FR), B. Schieffer (Hannover, DE)
| (O35) | ACE inhibitors stimulate endothelial COX-2 expression by a JNK-dependent ACE-signalling pathway. |
| K. Kohlstedt, R. Busse, I. Fleming (Frankfurt/Main, DE) | |
| (O36) | A new ACE on the table: ACE2 expression in human atherosclerosis. |
| J.C. Sluimer, I. Hamming, J.M. Gasc, H. Van Goor, L.H. Van den Akker, P. Corvol, M.J. Daemen, A.P. Bijnens (Maastricht, Groningen and Sittard, NL; Paris, FR) | |
| (O37) | Role of the ACE gene in renal and vascular complications of diabetes mellitus, experimental study in the mouse. |
| N. Bouby, N. Goncalves, C. Chollet, L. Cheval, M. Marre, F. Alhenc-Gelas (Paris, FR) | |
| (O38) | Bone marrow molecular alterations after myocardial infarction: impact on endothelial progenitor cells and modulation by ACE inhibition or statin treatment. |
| T. Thum, D. Fraccarollo, P. Galuppo, D. Tsikas, S. Froese, S. Frantz, G. Ertl, J. Bauersachs (Würzburg and Hannover, DE) | |
| (O39) | Anti-inflammatory properties of Ramiprilat: reduction of monocyte adhesion to angiotensin II-stimulated endothelium is associated with AT1 downregulation. |
| O. Soehnlein, A. Schmeisser, L. Lindbom, W.G. Daniel, Chr.D. Garlichs (Stockholm, SE; Dresden and Erlangen, DE) | |
| (O40) | Activation of phospholipase D by angiotensin II in HUVECS and HMVECS. |
| S. McHarg, J. Whatmore, A. Shore, for Institute of Clinical and Biomedical Science (Exeter, GB) |